Clinical observation on effect of Puerarin(葛根素) combined with meglumine adenosine cyclophosphate in treatment of refractory heart failure

Objective: To explore the clinical effect of Puerarin combined with meglumine adenosine cyclophosphate in treatment of refractory heart failure. Methods: Sixtytwo cases with refractory heart failure were randomly divided into control group( n =30) and treatment group ( n =32). The control group was treated with routine therapy including oxygen inhalation, diuretic, digitalis, vasodilator, angiotensin converting enzyme inhibitor(ACEI), antibiotic therapy, and supporting treatment. The treatment group was treated with Puerarin 0.4 g+5% glucose 250 ml intravenously drip once a day for 14 days, meglumine adenosine cyclophosphate 120 mg+5% glucose 250 ml intravenously, drip once a day for 14 days, as well as routine therapy. After two weeks, the clinical effects were compared between two groups. Results: The heart function and cardiac indexes were improved after treatment in two groups (all P 0.01), the difference was significant between treatment group and control group after treatment ( P 0.05). Conclusion: Combined Puerarin with meglumine adenosine cyclophosphate in treating refractory heart failure is effective and safe.